The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amryt Pharma Plans Trials Of Episalvan Product By End Of 2016

Thu, 09th Jun 2016 09:55

LONDON (Alliance News) - Amryt Pharma PLC on Thursday posted a loss for the nine months to the end of December as it said it expects to initiate a study on its epidermolysis bullosa treatment candidate around the end of 2016.

Amryt started trading in London in April following its reserve takeover by Fastnet Equity PLC, an AIM-listed investment company. Amryt is an orphan drug development firm which recently acquired German pharmaceutical firm Birken AG and Swiss biopharmaceutical company SomPharmaceuticals.

Birkin has developed a recently approved drug for partial thickness wounds and has a promising drug on its books for epidermolysis bullosa. SomPharmaceuticals is focused on developing medicines for patients with rare neuroendocrine diseases, including acromegaly and Cushing's disease.

The results for the nine months to the end of 2016, covering Fastnet, show a pretax loss of GBP1.3 million, driven by administrative expenses as the company generated no revenue. No comparative figures are available as the group changed its financial year to the calendar year from the end of March previously.

For the 12 months to the end of March 2015, the company made a GBP1.9 million pretax loss.

Amryt Non-Executive Chairman Harry Stratford said the group is planning to initiate a pivotal study on Episalvan, its epidermolysis bullosa treatment, around the end of 2016. The product secured European approval earlier this year for the treatment of partial thickness wounds, which Stratford said has "meaningfully de-risked" Episalvan.

"Amryt is focused on building a diversified portfolio of commercially attractive, propriety new drugs targeting best in class performance to help address some of these rare and debilitating illnesses for which there are currently no available treatments," he added.

Amryt shares were down 3.9% to 18.03 pence Thursday.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
11 Jan 2022 14:39

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

Read more
22 Nov 2021 11:37

Amryt to delist from AIM, concentrate on Nasdaq trading

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced its intention to cancel its shares from trading on AIM on Monday, with effect on 11 January.

Read more
9 Nov 2021 22:01

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

Read more
19 Oct 2021 15:54

Amryt Pharma granted another two US patents

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma updated the market on patents for its lead development candidate 'Oleogel-S10' on Tuesday, as well as its recently-acquired and third commercial product 'Mycapssa'.

Read more
14 Sep 2021 07:32

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

Read more
6 Aug 2021 14:41

IN BRIEF: Amryt hikes guidance on record second quarter results

IN BRIEF: Amryt hikes guidance on record second quarter results

Read more
6 Aug 2021 12:02

Record second quarter sees Amryt lift guidance further

(Sharecast News) - Amryt Pharma reported record second quarter results on Friday, raising its full-year guidance, as revenue in the three months ended 30 June came in at $62.8m, up from $46.2m year-on-year.

Read more
29 Jul 2021 17:10

EXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt

EXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt

Read more
17 Jun 2021 14:34

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

Read more
3 Jun 2021 19:20

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

Read more
3 Jun 2021 11:26

FDA grants Amryt's Oleogel-S10 priority review status

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Thursday that the United States Food and Drug Administration (FDA) has granted priority review status for the new drug application for 'Oleogel-S10', for the treatment of epidermolysis bullosa (EB).

Read more
2 Jun 2021 19:10

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

Read more
5 May 2021 19:20

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

Read more
6 Apr 2021 14:54

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

Read more
31 Mar 2021 11:50

Amryt completes rolling FDA submission for Oleogel-S10

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.